💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Canadian regulator OK's high-dose bolus regimen of Cardiome's Aggrastat

Published 07/17/2017, 10:34 AM
© Reuters.  Canadian regulator OK's high-dose bolus regimen of Cardiome's Aggrastat
72R_old
-
  • Health Canada approves Cardiome's (CRME +0.2%) supplemental New Drug Submission for a 25 mcg/kg bolus regimen of AGGRASTAT (tirofiban hydrochloride), now the recommended dose to reduce the rate of refractory ischemic conditions, new heart attacks and death in high-risk patients with non-ST elevation acute coronary syndrome who undergo percutaneous coronary intervention.
  • AGGRASTAT is an intravenous antagonist of the glycoprotein IIb/IIIa receptor which plays a key role in platelet aggregation. It is currently approved in Canada, in combination with heparin and acetylsalicylic acid, for the management of patients with unstable angina or non-Q-wave myocardial infarction.
  • Now read: What Happened With The Genzyme CVR Since August 2015


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.